当前位置: 首页 > 详情页

Platelets in Acute Coronary Syndrome Patients with High Platelet Reactivity after Dual Antiplatelet Therapy Exhibit Upregulation of miR-204-5p.

| 认领 | 导出 |

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Clinical Laboratory, Beijing An Zhen Hospital, Capital Medical University, China. [2]Department of Clinical Laboratory, Beijing An Zhen Hospital, Capital Medical University, China greatzxl@163.com. [3]Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, China. [4]Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical, China gongmaster@126.com. [5]Beijing Lab for Cardiovascular Precision Medicine, Beijing, China zhanghongjia722@hotmail.com.
出处:
ISSN:

摘要:
Acute coronary syndrome (ACS) patients treated with dual antiplatelet therapy (DAPT) show individual differences in platelet reactivity (PR). Here, we aim to find differences in the platelet microRNA (miRNA) expression profiles of high PR and low PR patients to serve as potential biomarkers. ADP-induced platelet aggregation (PAG) was used to determine PR. High-throughput sequencing technology was used to profile differentially expressed platelet miRNAs in high PR (PAG>50%) and low PR (PAG≤50%) patients. We used real-time quantitative reverse transcription-polymerase chain reactions (RT-qPCR) to validate the sequencing results. Finally, we statistically evaluated the diagnostic value of the miRNAs and explored their molecular function using bioinformatic analysis. The results show that miR-204-5p was confirmed to be significantly upregulated in the high PR group. The area under the ROC curve (AUC) of miR-204-5p was 0.667, and its expression significantly correlated with the Gensini score. Stepwise binary logistic regression analysis suggested that miR-204-5p expression level was an independent predictor of PR. Furthermore, bioinformatic analysis showed that miR-204-5p may be associated with platelet synapse formation and platelet vesicle release. Our data indicates that platelet miR-204-5p may serve as a novel biomarker of PR to guide treatment with antiplatelet drugs. © 2019 by the Association of Clinical Scientists, Inc.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 医学实验技术
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学实验技术
JCR分区:
出版当年[2017]版:
Q4 MEDICAL LABORATORY TECHNOLOGY
最新[2023]版:
Q3 MEDICAL LABORATORY TECHNOLOGY Q4 MEDICAL LABORATORY TECHNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Clinical Laboratory, Beijing An Zhen Hospital, Capital Medical University, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院